HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women

Share this content:
HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women
HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women

Fewer cervical cell anomalies were present on cervical cancer screens of young women who received the human papillomavirus (HPV) vaccine through a school-based program.1

"Eight years after a school-based HPV vaccination program was initiated in Alberta [Canada], 3-dose HPV vaccination has demonstrated early benefits, particularly against high-grade cervical abnormalities, which are more likely to progress to cervical cancer," reported Huiming Yang, MD, medical officer of health and medical director, Screening Programs, Alberta Health Services, Calgary, Alberta, Canada.

Alberta has both a school-based HPV vaccination program that provides 3 doses of the vaccine and a population-based screening program for cervical cancer. The HPV vaccination program began in 2008 for girls in grade 5 (age 10-11 years) along with a 3-year catch-up program for girls in grade 9 (age 14-15 years). The program expanded to include boys in 2014.

Researchers examined data from the first cohort of 10,204 women in the study population. More than half of the study participants (56%) were unvaccinated, and 44% had received 1 or more doses of the HPV vaccine before being screened for cervical cancer. Of the women who had been vaccinated, 84% received 3 or more doses. Among the unvaccinated women, 16.1% had cervical abnormalities, compared with 11.8% in the fully vaccinated group.

The researchers noted that implementing effective HPV vaccination with broad uptake will affect the harms and benefits of cervical screening. They wrote, “With population-based HPV vaccination, guidelines for cervical cancer screening may need to include a later age for screening initiation and/or a longer interval between screenings.”


1. Kim J, Bell C, Sun M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Can Med Assoc J. 2016 Jul 4. doi:10.1503/cmaj.151528. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs